ADIAL PHARMACEUTICALS INC (ADIL)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.92-7.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge ADIAL PHARMACEUTICALS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.19
Annual ending 2026-12-31
Revenue	—	46M
EPS	—	-2.6
Annual ending 2027-12-31
Revenue	—	4.4M
EPS	—	-0.61

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Complete integration and value creation from Azora acquisition	Adial completed the acquisition of Azora in June 2026, enhancing its strategic position.	Intact	Acquisition fails to integrate or deliver strategic benefits by FY26	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce losses and improve EPS trajectory	A primary condition in ADIAL PHARMACEUTICALS INC's published investment case. The stated target is EPS improves from -5.0 in Q3 2026 to better than -1.0 in FY26.	Broken	EPS remains below -1.0 for FY26 or worsens	Diluted EPS: $-11.25 per share FY2026-Q2; GAAP. Published target: EPS improves from -5.0 in Q3 2026 to better than -1.0 in FY26. Target period is not explicitly aligned with this observation. Source published Aug 14, 2026-11.25 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: dbf59f3d-45be-429f-96e0-9b9b86ec9bdb. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful commercialization of AD04 in Europe via Molteni partnership	It formed a partnership with Molteni Farmaceutici to commercialize AD04 in Europe.	Intact	Partnership fails to launch or generate commercial progress by FY26	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage financial obligations and optimize capital allocation	Despite losses, management is focused on managing financial obligations and capital allocation.	Under Pressure	Financial obligations worsen or capital allocation deteriorates by FY26	Stockholders' equity < $2.5M vs >= $2.5M target Nasdaq delisting notice due to stockholders' equity below $2.5M minimum; Milestone Warrants reclassified as liability. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 1
2026-07-25	Unavailable	Unavailable	1 / 1
2026-07-26	Unavailable	Unavailable	1 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	1 / 1
2026-07-29	Unavailable	Unavailable	1 / 1
2026-07-30	Unavailable	Unavailable	1 / 1
2026-07-31	Unavailable	Unavailable	1 / 1
2026-08-01	Unavailable	Unavailable	1 / 1
2026-08-02	Unavailable	Unavailable	1 / 1
2026-08-03	Unavailable	Unavailable	1 / 1
2026-08-04	Unavailable	Unavailable	1 / 1
2026-08-05	Unavailable	Unavailable	1 / 1
2026-08-06	Unavailable	Unavailable	1 / 1
2026-08-07	Unavailable	Unavailable	1 / 1
2026-08-08	Unavailable	Unavailable	2 / 1
2026-08-09	Unavailable	Unavailable	2 / 1
2026-08-10	Unavailable	Unavailable	2 / 1
2026-08-11	Unavailable	Unavailable	2 / 1
2026-08-12	Unavailable	Unavailable	2 / 1
2026-08-13	Unavailable	Unavailable	2 / 1
2026-08-14	Unavailable	Unavailable	1 / 1
2026-08-15	Unavailable	Unavailable	1 / 1
2026-08-16	Unavailable	Unavailable	1 / 1
2026-08-17	Unavailable	Unavailable	1 / 1
2026-08-18	Unavailable	Unavailable	1 / 1
2026-08-19	Unavailable	Unavailable	1 / 1
2026-08-20	Unavailable	Unavailable	2 / 1
2026-08-21	Unavailable	Unavailable	2 / 1
2026-08-22	Unavailable	Unavailable	2 / 1
2026-08-23	Unavailable	Unavailable	2 / 1
2026-08-24	Unavailable	Unavailable	2 / 1
2026-08-25	Unavailable	Unavailable	2 / 1
2026-08-26	Unavailable	Unavailable	2 / 1
2026-08-27	Unavailable	Unavailable	2 / 1
2026-08-28	Unavailable	Unavailable	2 / 1
2026-08-29	Unavailable	Unavailable	2 / 1
2026-08-30	Unavailable	Unavailable	2 / 1
2026-08-31	Unavailable	Unavailable	2 / 1
2026-09-01	Unavailable	Unavailable	2 / 1
2026-09-02	Unavailable	Unavailable	2 / 1
2026-09-03	Unavailable	Unavailable	2 / 1
2026-09-04	Unavailable	Unavailable	2 / 1
2026-09-05	Unavailable	Unavailable	2 / 1
2026-09-06	Unavailable	Unavailable	2 / 1
2026-09-07	Unavailable	Unavailable	2 / 1
2026-09-08	Unavailable	Unavailable	2 / 1
2026-09-09	Unavailable	Unavailable	2 / 1
2026-09-10	Unavailable	Unavailable	2 / 1
2026-09-11	Unavailable	Unavailable	2 / 1
2026-09-12	Unavailable	Unavailable	2 / 1
2026-09-13	Unavailable	Unavailable	2 / 1
2026-09-14	Unavailable	Unavailable	2 / 1
2026-09-15	Unavailable	Unavailable	2 / 1
2026-09-16	Unavailable	Unavailable	2 / 1
2026-09-17	Unavailable	Unavailable	2 / 1
2026-09-18	Unavailable	Unavailable	2 / 1
2026-09-19	Unavailable	Unavailable	2 / 1
2026-09-20	Unavailable	Unavailable	2 / 1
2026-09-21	Unavailable	Unavailable	2 / 1
2026-09-22	Unavailable	Unavailable	2 / 1
2026-09-23	Unavailable	Unavailable	2 / 1
2026-09-24	Unavailable	Unavailable	2 / 1
2026-09-25	Unavailable	Unavailable	2 / 1
2026-09-26	Unavailable	Unavailable	2 / 1
2026-09-27	Unavailable	Unavailable	2 / 1
2026-09-28	Unavailable	Unavailable	2 / 1
2026-09-29	Unavailable	Unavailable	2 / 1
2026-09-30	Unavailable	Unavailable	2 / 1
2026-10-01	Unavailable	Unavailable	2 / 1
2026-10-02	Unavailable	Unavailable	2 / 1
2026-10-03	Unavailable	Unavailable	2 / 1
2026-10-04	Unavailable	Unavailable	2 / 1
2026-10-05	Unavailable	Unavailable	2 / 1
2026-10-06	Unavailable	Unavailable	2 / 1
2026-10-07	Unavailable	Unavailable	2 / 1
2026-10-08	Unavailable	Unavailable	2 / 1
2026-10-09	Unavailable	Unavailable	2 / 1
2026-10-10	Unavailable	Unavailable	2 / 1
2026-10-11	Unavailable	Unavailable	2 / 1
2026-10-12	Unavailable	Unavailable	2 / 1
2026-10-13	Unavailable	Unavailable	2 / 1
2026-10-14	Unavailable	Unavailable	2 / 1
2026-10-15	Unavailable	Unavailable	2 / 1
2026-10-16	Unavailable	Unavailable	2 / 1
2026-10-17	Unavailable	Unavailable	2 / 1
2026-10-18	Unavailable	Unavailable	2 / 1
2026-10-19	Unavailable	Unavailable	2 / 1
2026-10-20	Unavailable	Unavailable	2 / 1
2026-10-21	Unavailable	Unavailable	2 / 1
2026-10-22	Unavailable	Unavailable	2 / 1
2026-10-23	Unavailable	Unavailable	2 / 1
2026-10-24	Unavailable	Unavailable	2 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	2	0
2026-06-01	2	1
2026-07-01	2	1
2026-08-01	3	1
2026-09-01	3	1
2026-10-01	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Complete integration and value creation from Azora acquisitionQualitative condition
Reduce losses and improve EPS trajectoryPublished status: Broken
Successful commercialization of AD04 in Europe via Molteni partnershipQualitative condition
Manage financial obligations and optimize capital allocationPublished status: Under Pressure

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

4.1%Typical daily move · historical

Downside history

-85.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ADIAL PHARMACEUTICALS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative, loss-making biotech exposure, not a proven compounder. The long-term thesis is in a watch state, with low confidence because management has been volatile and recent financial performance is weak.

What's priced into ADIAL PHARMACEUTICALS INC

The evidence snapshot provides no valuation or expectations data, so whether the stock is cheap, fair, or expensive versus peers cannot be assessed. There is also not enough evidence to say what the market already assumes.

What the fundamentals likely do

Near term, earnings risk is elevated given the company’s small size and erratic recent surprises; the snapshot estimates a 63% chance of a next-quarter miss. Cash rose to $28.7 million at June 30, 2026, which management says funds expenses into the second half of 2027, but AT177 is still in IND-enabling studies, an early stage before clinical testing, with an IND filing planned for the first half of 2027. A CEO transition and a delisting-related notice add uncertainty, while the supplied evidence does not establish their outcomes.

What ADIAL PHARMACEUTICALS INC hinges on

Over the multi-year view, a key test is whether ADIL files the planned IND for AT177 and secures further financing for development milestones. The outlook also depends on whether AD04 receives renewed development progress, since the latest supplied disclosure shifts lead focus to AT177, and on whether broader healthcare-sector momentum persists. Weakening jobs data or weaker results from sector bellwethers could weigh on the sector backdrop.